Top

Published in:

Open Access 01-12-2012 | Review

Review of pyronaridine anti-malarial properties and product characteristics

Published in: Malaria Journal | Issue 1/2012

Abstract

Pyronaridine was synthesized in 1970 at the Institute of Chinese Parasitic Disease and has been used in China for over 30 years for the treatment of malaria. Pyronaridine has high potency against Plasmodium falciparum, including chloroquine-resistant strains. Studies in various animal models have shown pyronaridine to be effective against strains resistant to other anti-malarials, including chloroquine. Resistance to pyronaridine appears to emerge slowly and is further retarded when pyronaridine is used in combination with other anti-malarials, in particular, artesunate. Pyronaridine toxicity is generally less than that of chloroquine, though evidence of embryotoxicity in rodents suggests use with caution in pregnancy. Clinical pharmacokinetic data for pyronaridine indicates an elimination T_1/2 of 13.2 and 9.6 days, respectively, in adults and children with acute uncomplicated falciparum and vivax malaria in artemisinin-combination therapy. Clinical data for mono or combined pyronaridine therapy show excellent anti-malarial effects against P. falciparum and studies of combination therapy also show promise against Plasmodium vivax. Pyronaridine has been developed as a fixed dose combination therapy, in a 3:1 ratio, with artesunate for the treatment of acute uncomplicated P. falciparum malaria and blood stage P. vivax malaria with the name of Pyramax® and has received Positive Opinion by European Medicines Agency under the Article 58 procedure.

Available only for authorised users

Zheng XY, Chen C, Gao FH, Zhu PE, Guo HZ: Synthesis of new antimalarial drug pyronaridine and its analogues (author's transl). Yao Xue Xue Bao. 1982, 17: 118-125.PubMed

Zheng XY, Xia Y, Gao FH, Chen C: Synthesis of 7351, a new antimalarial drug (author's transl). Yao Xue Xue Bao. 1979, 14: 736-737.PubMed

Chang C, Lin-Hua T, Jantanavivat C: Studies on a new antimalarial compound: pyronaridine. Trans R Soc Trop Med Hyg. 1992, 86: 7-10. 10.1016/0035-9203(92)90414-8.PubMed

Chen YC, Fleckenstein L: Improved assay method for the determination of pyronaridine in plasma and whole blood by high-performance liquid chromatography for application to clinical pharmacokinetic studies. J Chromatogr B Biomed Sci Appl. 2001, 752: 39-46. 10.1016/S0378-4347(00)00512-0.PubMed

Shao BR: A review of antimalarial drug pyronaridine. Chin Med J (Engl). 1990, 103: 428-434.

Ramanathan S, Karupiah S, Nair NK, Olliaro PL, Navaratnam V, Wernsdorfer WH, Mansor SM: A new and simple solid-phase extraction method for LC determination of pyronaridine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2005, 824: 45-50. 10.1016/j.jchromb.2005.06.034.PubMed

Adegoke OA, Babalola CP, Oshitade OS, Famuyiwa AA: Determination of the physicochemical properties of pyronaridine - a new antimalarial drug. Pak J Pharm Sci. 2006, 19: 1-6.PubMed

Ruscoe JE, Tingle MD, O'Neill PM, Ward SA, Park BK: Effect of disposition of mannich antimalarial agents on their pharmacology and toxicology. Antimicrob Agents Chemother. 1998, 42: 2410-2416.PubMedCentralPubMed

Childs GE, Hausler B, Milhous W, Chen C, Wimonwattrawatee T, Pooyindee N, Boudreau EF: In vitro activity of pyronaridine against field isolates and reference clones of Plasmodium falciparum. Am J Trop Med Hyg. 1988, 38: 24-29.PubMed

10.

Basco LK, Le Bras J: In vitro activity of pyronaridine against African strains of Plasmodium falciparum. Ann Trop Med Parasitol. 1992, 86: 447-454.PubMed

11.

Vivas L, Rattray L, Stewart L, Bongard E, Robinson B, Peters W, Croft SL: Anti-malarial efficacy of pyronaridine and artesunate in combination in vitro and in vivo. Acta Trop. 2008, 105: 222-228. 10.1016/j.actatropica.2007.12.005.PubMed

12.

Basco LK, Le Bras J: In vitro susceptibility of Cambodian isolates of Plasmodium falciparum to halofantrine, pyronaridine and artemisinin derivatives. Ann Trop Med Parasitol. 1994, 88: 137-144.PubMed

13.

Alin MH, Bjorkman A, Ashton M: In vitro activity of artemisinin, its derivatives, and pyronaridine against different strains of Plasmodium falciparum. Trans R Soc Trop Med Hyg. 1990, 84: 635-637. 10.1016/0035-9203(90)90129-3.PubMed

14.

Pradines B, Mabika Mamfoumbi M, Parzy D, Owono Medang M, Lebeau C, Mourou Mbina JR, Doury JC, Kombila M: In vitro susceptibility of African isolates of Plasmodium falciparum from Gabon to pyronaridine. Am J Trop Med Hyg. 1999, 60: 105-108.PubMed

15.

Pradines B, Tall A, Fusai T, Spiegel A, Hienne R, Rogier C, Trape JF, Le Bras J, Parzy D: In vitro activities of benflumetol against 158 Senegalese isolates of Plasmodium falciparum in comparison with those of standard antimalarial drugs. Antimicrob Agents Chemother. 1999, 43: 418-420.PubMedCentralPubMed

16.

Pradines B, Tall A, Parzy D, Spiegel A, Fusai T, Hienne R, Trape JF, Doury JC: In-vitro activity of pyronaridine and amodiaquine against African isolates (Senegal) of Plasmodium falciparum in comparison with standard antimalarial agents. J Antimicrob Chemother. 1998, 42: 333-339. 10.1093/jac/42.3.333.PubMed

17.

Ringwald P, Bickii J, Basco LK: In vitro activity of antimalarials against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon. Am J Trop Med Hyg. 1996, 55: 254-258.PubMed

18.

Wu LJ, Rabbege JR, Nagasawa H, Jacobs G, Aikawa M: Morphological effects of pyronaridine on malarial parasites. Am J Trop Med Hyg. 1988, 38: 30-36.PubMed

19.

Auparakkitanon S, Chapoomram S, Kuaha K, Chirachariyavej T, Wilairat P: Targeting of hematin by the antimalarial pyronaridine. Antimicrob Agents Chemother. 2006, 50: 2197-2200. 10.1128/AAC.00119-06.PubMedCentralPubMed

20.

Dorn A, Vippagunta SR, Matile H, Jaquet C, Vennerstrom JL, Ridley RG: An assessment of drug-haematin binding as a mechanism for inhibition of haematin polymerisation by quinoline antimalarials. Biochem Pharmacol. 1998, 55: 727-736. 10.1016/S0006-2952(97)00510-8.PubMed

21.

Famin O, Krugliak M, Ginsburg H: Kinetics of inhibition of glutathione-mediated degradation of ferriprotoporphyrin IX by antimalarial drugs. Biochem Pharmacol. 1999, 58: 59-68. 10.1016/S0006-2952(99)00059-3.PubMed

22.

Gupta S, Thapar MM, Mariga ST, Wernsdorfer WH, Bjorkman A: Plasmodium falciparum: in vitro interactions of artemisinin with amodiaquine, pyronaridine, and chloroquine. Exp Parasitol. 2002, 100: 28-35. 10.1006/expr.2001.4659.PubMed

23.

Davis TM, Hamzah J, Ilett KF, Karunajeewa HA, Reeder JC, Batty KT, Hackett S, Barrett PH: In vitro interactions between piperaquine, dihydroartemisinin, and other conventional and novel antimalarial drugs. Antimicrob Agents Chemother. 2006, 50: 2883-2885. 10.1128/AAC.00177-06.PubMedCentralPubMed

24.

Ringwald P, Eboumbou EC, Bickii J, Basco LK: In vitro activities of pyronaridine, alone and in combination with other antimalarial drugs, against Plasmodium falciparum. Antimicrob Agents Chemother. 1999, 43: 1525-1527.PubMedCentralPubMed

25.

Wu LJ: [Ultrastructural study on the effect of pyronaridine on the erythrocytic stages of chloroquine-resistant strain of Plasmodium berghei](in Chinese). Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 1986, 4: 263-266.PubMed

26.

Wu LJ: [Effect of pyronaridine on ultrastructure of erythrocytic forms of Plasmodium berghei in mice] (in Chinese). Zhongguo Yao Li Xue Bao. 1985, 6: 280-283.PubMed

27.

Kawai S, Kano S, Chang C, Suzuki M: The effects of pyronaridine on the morphology of Plasmodium falciparum in Aotus trivirgatus. Am J Trop Med Hyg. 1996, 55: 223-229.PubMed

28.

Auparakkitanon S, Noonpakdee W, Ralph RK, Denny WA, Wilairat P: Antimalarial 9-anilinoacridine compounds directed at hematin. Antimicrob Agents Chemother. 2003, 47: 3708-3712. 10.1128/AAC.47.12.3708-3712.2003.PubMedCentralPubMed

29.

Auparakkitanon S, Wilairat P: Antimalarial activity of concanamycin A alone and in combination with pyronaridine. Southeast Asian J Trop Med Public Health. 2006, 37: 619-621.PubMed

30.

Chavalitshewinkoon P, Wilairat P, Gamage S, Denny W, Figgitt D, Ralph R: Structure-activity relationships and modes of action of 9-anilinoacridines against chloroquine-resistant Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 1993, 37: 403-406. 10.1128/AAC.37.3.403.PubMedCentralPubMed

31.

Auparakkitanon S, Wilairat P: Cleavage of DNA induced by 9-anilinoacridine inhibitors of topoisomerase II in the malaria parasite Plasmodium falciparum. Biochem Biophys Res Commun. 2000, 269: 406-409. 10.1006/bbrc.2000.2305.PubMed

32.

Elueze EI, Croft SL, Warhurst DC: Activity of pyronaridine and mepacrine against twelve strains of Plasmodium falciparum in vitro. J Antimicrob Chemother. 1996, 37: 511-518. 10.1093/jac/37.3.511.PubMed

33.

Chen KY, Ha SH, Zhan CQ, Shao BR: [Sensitivities of different stages of erythrocytic Plasmodium falciparum to pyronaridine](in Chinese). Zhongguo Yao Li Xue Bao. 1987, 8: 348-351.PubMed

34.

Kotecka BM, Barlin GB, Edstein MD, Rieckmann KH: New quinoline di-Mannich base compounds with greater antimalarial activity than chloroquine, amodiaquine, or pyronaridine. Antimicrob Agents Chemother. 1997, 41: 1369-1374.PubMedCentralPubMed

35.

Li J, Huang WJ: [Effects of artesunate, pyronaridine and hydroxypiperaquine on chloroquine-sensitive and chloroquine-resistant isolates of Plasmodium falciparum in vitro](in Chinese). Zhongguo Yao Li Xue Bao. 1988, 9: 83-86.PubMed

36.

Fu S, Bjorkman A, Wahlin B, Ofori-Adjei D, Ericsson O, Sjoqvist F: In vitro activity of chloroquine, the two enantiomers of chloroquine, desethylchloroquine and pyronaridine against Plasmodium falciparum. Br J Clin Pharmacol. 1986, 22: 93-96.PubMedCentralPubMed

37.

Schildbach S, Wernsdorfer WH, Suebsaeng L, Rooney W: In vitro sensitivity of multiresistant Plasmodium falciparum to new candidate antimalarial drugs in western Thailand. Southeast Asian J Trop Med Public Health. 1990, 21: 29-38.PubMed

38.

Elueze E, Croft SL, Warhurst DC: Uptake of 3[H] pyronaridine by Plasmodium falciparum infected erythrocytes in vitro . Cellular Pharmacology. 1996, 3: 397-403.

39.

Caramello P, Canta F, Cavecchia I, Sergi G, Balbiano R, Ariaudo S, Audagnotto S, Di Perri G: Chemosusceptibility analysis of Plasmodium falciparum imported malaria in Italy. Diagn Microbiol Infect Dis. 2005, 52: 107-112. 10.1016/j.diagmicrobio.2005.01.002.PubMed

40.

Agnamey P, Moyou SR, Brasseur P, Galega PF: [Center of multidrug-resistant malaria in a forest zone of Cameroon revisited after 14 years](in French). Med Trop (Mars). 2002, 62: 141-144.

41.

Warsame M, Wernsdorfer WH, Payne D, Bjorkman A: Positive relationship between the response of Plasmodium falciparum to chloroquine and pyronaridine. Trans R Soc Trop Med Hyg. 1991, 85: 570-571. 10.1016/0035-9203(91)90345-Y.PubMed

42.

Peters W, Robinson BL: The chemotherapy of rodent malaria. LV. Interactions between pyronaridine and artemisinin. Ann Trop Med Parasitol. 1997, 91: 141-145.PubMed

43.

Wu LJ: [Effects of large doses of pyronaridine and chloroquine on the ultrastructure of the erythrocytic stages of pyronaridine-resistant line of Plasmodium berghei] (in Chinese). Zhongguo Yao Li Xue Bao. 1988, 9: 87-89.PubMed

44.

Li GD, Liu SQ, Ye XY, Qu FY: [Detection of 54-kDa protein overexpressed by chloroquine-resistant Plasmodium berghei ANKA strain in pyronaridine-resistant P berghei ANKA strain] (in Chinese). Zhongguo Yao Li Xue Bao. 1995, 16: 17-20.PubMed

45.

Shi X, Ye X, Cai Y, Ha S, Yao J: [Determination of polyamines in pyronaridine-sensitive and -resistant Plasmodium berghei-infected erythrocytes] (in Chinese). Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 1998, 16: 109-112.PubMed

46.

Shao BR, Ye XY: [Delay in emergence of resistance to pyronaridine phosphate in Plasmodium berghei] (in Chinese). Zhongguo Yao Li Xue Bao. 1986, 7: 463-467.PubMed

47.

Xiao SH, Yao JM, Utzinger J, Cai Y, Chollet J, Tanner M: Selection and reversal of Plasmodium berghei resistance in the mouse model following repeated high doses of artemether. Parasitol Res. 2004, 92: 215-219. 10.1007/s00436-003-1029-9.PubMed

48.

Shao BR, Ye XY, Zheng H: [Stability of drug resistance of a pyronaridine-resistant line of Plasmodium berghei] (in Chinese). Zhongguo Yao Li Xue Bao. 1985, 6: 183-105.PubMed

49.

Peters W, Robinson BL: The chemotherapy of rodent malaria. XLVII. Studies on pyronaridine and other Mannich base antimalarials. Ann Trop Med Parasitol. 1992, 86: 455-465.PubMed

50.

Peters W: The chemotherapy of rodent malaria. LVII. Drug combinations to impede the selection of drug resistance, Part 1: Which model is appropriate?. Ann Trop Med Parasitol. 1999, 93: 569-587. 10.1080/00034989958087.PubMed

51.

Peters W, Robinson BL: The chemotherapy of rodent malaria. LVIII. Drug combinations to impede the selection of drug resistance, Part. 2: The new generation–artemisinin or artesunate with long-acting blood schizontocides. Ann Trop Med Parasitol. 2000, 94: 23-35. 10.1080/00034980057581.PubMed

52.

Yang H, Liu D, Huang K, Zhang C, Li C: [Longitudinal surveillance of sensitivity of Plasmodium falciparum to pyronaridine in south Yunnan] (in Chinese). Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 1998, 16: 81-83.PubMed

53.

Fan B, Zhao W, Ma X, Huang Z, Wen Y, Yang J, Yang Z: [In vitro sensitivity of Plasmodium falciparum to chloroquine, piperaquine, pyronaridine and artesunate in Yuxi prefecture of Yunnan province] (in Chinese). Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 1998, 16: 460-462.PubMed

54.

Yang H, Liu D, Dong Y, Yang P, Liu R, Zhang B, Zhang C: [Sensitivity of Plasmodium falciparum to seven antimalarials in China-Laos border] (in Chinese). Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 1995, 13: 111-113.PubMed

55.

Liu DQ, Feng XP, Liu RJ, Zhang CY: [Establishment of in vitro microtest for determining sensitivity of Plasmodium falciparum to pyronaridine] (in Chinese). Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2006, 24: 102-105.PubMed

56.

Shao BR, Huang ZS, Shi XH, Meng F: A 5-year surveillance of sensitivity in vivo of Plasmodium falciparum to pyronaridine/sulfadoxine/pyrimethamine in Diaoluo area, Hainan Province. Southeast Asian J Trop Med Public Health. 1991, 22: 65-67.PubMed

57.

Looareesuwan S, Kyle DE, Viravan C, Vanijanonta S, Wilairatana P, Wernsdorfer WH: Clinical study of pyronaridine for the treatment of acute uncomplicated falciparum malaria in Thailand. Am J Trop Med Hyg. 1996, 54: 205-209.PubMed

58.

Ye XY, Shao BR: [Tissue schizontocidal action and acute toxicity of trifluoroacetyl primaquine] (in Chinese). Zhongguo Yao Li Xue Bao. 1990, 11: 359-362.PubMed

59.

Shi XH, Shao BR, Ye XY: [Combined action of pyronaridine and sulfadoxine/pyrimethamine against Plasmodium berghei ANKA strain in mice] (in Chinese). Zhongguo Yao Li Xue Bao. 1990, 11: 66-69.PubMed

60.

Liu D, Sun J, Fu X, Zhang J, Wang Y, Ren D, Xu Y: Experimental observation on injection of new antimalarial '7351'. 1973, Shanghai: Chinese Academy of Medical Sciences, 148-155.

61.

Zhang JX, Lin BY, Chen KY, Shao BR: [On the residual activity of pyronaridine against Plasmodium cynomolgi in rhesus monkeys] (in Chinese). Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 1986, 4: 129-131.PubMed

62.

Chen KY, Shao BR, Zhang JX, Lin BY: [Therapeutic effect of pyronaridine given intragastrically on Plasmodium cynomolgi-infected rhesus monkeys] (in Chinese). Yao Xue Xue Bao. 1985, 20: 309-311.PubMed

63.

Institute of Parasitic Diseases Chinese Academy of Medical Sciences: [Experimental studies on chemotherapeutic effects and toxicities of a new antimalarial drug 7351 (author's transl)]. Yao Xue Xue Bao. 1980, 15: 630-632.

64.

Basco LK, Ringwald P, Franetich JF, Mazier D: Assessment of pyronaridine activity in vivo and in vitro against the hepatic stages of malaria in laboratory mice. Trans R Soc Trop Med Hyg. 1999, 93: 651-652. 10.1016/S0035-9203(99)90085-8.PubMed

65.

Shao BR, Ye XY, Zheng H: [Residual blood schizontocidal activity of pyronaridine against rodent malaria] (in Chinese). Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 1984, 2: 232-233. 242PubMed

66.

Shao BR, Huang ZS, Shi XH, Zhan CQ, Meng F, Ye XY, Huang J, Ha SH: Antimalarial and toxic effect of triple combination of pyronaridine, sulfadoxine and pyrimethamine. Southeast Asian J Trop Med Public Health. 1989, 20: 257-263.PubMed

67.

Shao BR, Ye XY, Chu YH: Comparison of effects of pyronaridine, amodiaquine, mefloquine and qinghaosu on rodent malaria. Southeast Asian J Trop Med Public Health. 1992, 23: 59-63.PubMed

68.

Dutta GP, Puri SK, Awasthi A, Mishra M, Tripathi R: Pyronaridine: an effective antimalarial against multidrug-resistant malaria. Life Sci. 2000, 67: 759-763. 10.1016/S0024-3205(00)00670-6.PubMed

69.

Tripathi R, Umesh A, Mishra M, Puri SK, Dutta GP: Plasmodium yoelii nigeriensis (MDR)-efficacy of oral pyronaridine against multidrug-resistant malaria in Swiss mice. Exp Parasitol. 2000, 94: 190-193. 10.1006/expr.1999.4470.PubMed

70.

Chen KY, Lin BY, Zhang JX, Shao BR: [7 antimalarials in the treatment of mice experimentally infected with pyronaridine-resistant Plasmodium berghei] (in Chinese). Zhongguo Yao Li Xue Bao. 1983, 4: 269-273.PubMed

71.

Chen C, Zheng X: Development of the new antimalarial drug pyronaridine: a review. Biomed Environ Sci. 1992, 5: 149-160.PubMed

72.

Chavalitshewinkoon-Petmitr P, Pongvilairat G, Auparakkitanon S, Wilairat P: Gametocytocidal activity of pyronaridine and DNA topoisomerase II inhibitors against multidrug-resistant Plasmodium falciparum in vitro. Parasitol Int. 2000, 48: 275-280. 10.1016/S1383-5769(99)00028-8.PubMed

73.

Ringwald P, Meche FS, Basco LK: Short report: effects of pyronaridine on gametocytes in patients with acute uncomplicated falciparum malaria. Am J Trop Med Hyg. 1999, 61: 446-448.PubMed

74.

Ringwald P, Bickii J, Same-Ekobo A, Basco LK: Pyronaridine for treatment of Plasmodium ovale and Plasmodium malariae infections. Antimicrob Agents Chemother. 1997, 41: 2317-2319.PubMedCentralPubMed

75.

Zheng X: Studies of new antimalarial '7351'. 1972, Shanghai: Chinese Academy of Medical Sciences, 165-173.

76.

Ni YC, Zhan CQ, Ha SH, Shao BR: [The embryotoxicity of a new antimalarial pyronaridine in rats] (in Chinese). Yao Xue Xue Bao. 1982, 17: 401-406.PubMed

77.

Naisbitt DJ, Williams DP, O'Neill PM, Maggs JL, Willock DJ, Pirmohamed M, Park BK: Metabolism-dependent neutrophil cytotoxicity of amodiaquine: A comparison with pyronaridine and related antimalarial drugs. Chem Res Toxicol. 1998, 11: 1586-1595. 10.1021/tx980148k.PubMed

78.

Shao BR, Zhan CQ, Ha SH: [Evaluation of the phototoxicity of five antimalarial agents and praziquantel in mice] (in Chinese). Zhongguo Yao Li Xue Bao. 1986, 7: 273-275.PubMed

79.

Fu S, Xiao SH: Pyronaridine: A new antimalarial drug. Parasitol Today. 1991, 7: 310-313. 10.1016/0169-4758(91)90267-R.PubMed

80.

Shao BR, Zhan CQ, Chen KY, Ye XY, Lin BY, Ha SH, Zhang JX: Experimental studies on combinations of pyronaridine/primaquine versus chloroquine/primaquine. Chin Med J (Engl). 1990, 103: 1024-1026.

81.

Shao BR, Zhan CQ, Ha SH: [Influence of pyronaridine phosphate on three-generation reproduction in rats] (in Chinese). Zhongguo Yao Li Xue Bao. 1985, 6: 131-134.PubMed

82.

Investigators: Brochure: Pyramax Tablets and Granules (Pyronaridine : artesunate). 2011

83.

Ni YC, Xu YQ, Shao BR: Mutagenicity of a new antimalarial drug, pyronaridine, in the Salmonella/microsome system (author's transl). Zhongguo Yao Li Xue Bao. 1982, 3: 51-55.PubMed

84.

Shao BR, Xu YQ: [The mouse micronucleus test for mutagenicity of pyronaridine, chloroquine, quinacrine, primaquine, furapyrimidone and phenthiourezine] (in Chinese). Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 1988, 6: 272-274.PubMed

85.

Zhan CQ, Ha SH, Shao BR: Chromosomal aberration test with pyronaridine, furapyrimidone and furazolidone. 1986, Shanghai: 1986, 150-152.

86.

Maier P, Schmid W: The non-induction of micronuclei by quinacrine. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 1975, 30: 299-301.PubMed

87.

Hayashi M, Sofuni T, Ishidate M: An application of Acridine Orange fluorescent staining to the micronucleus test. Mutation Research Letters. 1983, 120: 241-247. 10.1016/0165-7992(83)90096-9.

88.

Shao BR, Zhan CQ, Ha SH, Ni YC: [Dominant lethal test with pyronaridine on male mice] (in Chinese). Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 1983, 1: 121-123.PubMed

89.

Neftel KA, Woodtly W, Schmid M, Frick PG, Fehr J: Amodiaquine induced agranulocytosis and liver damage. Br Med J (Clin Res Ed). 1986, 292: 721-723. 10.1136/bmj.292.6522.721.

90.

Lee J, Son J, Chung SJ, Lee ES, Kim DH: In vitro and in vivo metabolism of pyronaridine characterized by low-energy collision-induced dissociation mass spectrometry with electrospray ionization. J Mass Spectrom. 2004, 39: 1036-1043. 10.1002/jms.663.PubMed

91.

Yuan BJ, Li BC, Shen NC: [Evaluation of the phototoxic effects of chloroquine and eleven other antimalarials in mice] (in Chinese). Zhongguo Yao Li Xue Bao. 1986, 7: 468-470.PubMed

92.

Naik H, Wei SY, Schmidt MS, Murry DJ, Fleckenstein L: Development and validation of a liquid chromatography-mass spectrometry assay for the determination of pyronaridine in human urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2007, 853: 80-87. 10.1016/j.jchromb.2007.02.054.PubMed

93.

Feng Z, Jiang NX, Wang CY, Zhang W: [Pharmacokinetics of pyronaridine, an antimalarial in rabbits] (in Chinese). Yao Xue Xue Bao. 1986, 21: 801-805.PubMed

94.

Feng Z, Wang C: Studies on absorption distribution and excretion of '7351' by intramuscular injection. 1973, Shanghai: Chinese Academy of Medical Sciences, 144-147.

95.

Jayaraman SD, Ismail S, Nair NK, Navaratnam V: Determination of pyronaridine in blood plasma by high-performance liquid chromatography for application in clinical pharmacological studies. J Chromatogr B Biomed Sci Appl. 1997, 690: 253-257. 10.1016/S0378-4347(96)00410-0.PubMed

96.

Naik H, Imming P, Schmidt MS, Murry DJ, Fleckenstein L: Development and validation of a liquid chromatography-mass spectrometry assay for the determination of pyronaridine in human blood for application to clinical pharmacokinetic studies. J Pharm Biomed Anal. 2007, 45: 112-119. 10.1016/j.jpba.2007.06.018.PubMed

97.

Wages SA, Patchen LC, Churchill FC: Analysis of blood and urine samples from Macaca mulata for pyronaridine by high-performance liquid chromatography with electrochemical detection. J Chromatogr. 1990, 527: 115-126.PubMed

98.

O'Neill PM, Mukhtar A, Stocks PA, Randle LE, Hindley S, Ward SA, Storr RC, Bickley JF, O'Neil IA, Maggs JL, Hughes RH, Winstanley PA, Bray PG, Park BK: Isoquine and related amodiaquine analogues: a new generation of improved 4-aminoquinoline antimalarials. J Med Chem. 2003, 46: 4933-4945. 10.1021/jm030796n.PubMed

99.

Feng Z, Wu ZF, Wang CY, Jiang AG: [Distribution and excretion of 3 H-pyronaridine in mice] (in Chinese). Yao Xue Xue Bao. 1988, 23: 629-632.PubMed

100.

Park SH, Pradeep K: Absorption, distribution, excretion, and pharmacokinetics of 14 C-pyronaridine tetraphosphate in male and female Sprague–Dawley rats. J Biomed Biotechnol. 2010, 2010: 590707-PubMedCentralPubMed

101.

Babalola CP, Scriba GK, Sowunmi A, Alawode OA: Liquid chromatographic determination of pyronaridine in human plasma and oral dosage form. J Chromatogr B Analyt Technol Biomed Life Sci. 2003, 795: 265-272. 10.1016/S1570-0232(03)00591-9.PubMed

102.

Feng Z, Wu ZF, Wang CY, Jiang NX: [Pharmacokinetics of pyronaridine in malaria patients] (in Chinese). Zhongguo Yao Li Xue Bao. 1987, 8: 543-546.PubMed

103.

Methaneethorn J, Duparc S, Borghini-Fuhrer I, Shin C, Jung D, Fleckenstein L: Population pharmacokinetics of pyronaridine following oral pyronaridine/artesunate treatment in healthy and malaria infected subjects. American Society of Tropical Medicine and Hygiene 60th Annual Meeting. 2011, 85: 199-

104.

Ramharter M, Kurth F, Schreier AC, Nemeth J, Glasenapp I, Belard S, Schlie M, Kammer J, Koumba PK, Cisse B, Mordmüller B, Lell B, Issifou S, Oeuvray C, Fleckenstein L, Kremsner PG: Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J Infect Dis. 2008, 198: 911-919. 10.1086/591096.PubMed

105.

Huang ZS, Feng Z, Meng F, Zeng LH, Lin X, Zheng Y, Xing QF, Guo RN: [Therapeutic effect of pyronaridine in plain tablets and enteric-coated tablets in falciparum malaria patients] (in Chinese). Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 1989, 7: 19-21.PubMed

106.

Cai XZ, Pang XJ, Chen W: Treatment of 10 cases of chloroquine-resistant falciparum malaria with pyronaridine. Chinese Journal of Parasitology and Parasitic Diseases. 1987, 5: 228-

107.

Ringwald P, Bickii J, Basco L: Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa. Lancet. 1996, 347: 24-28. 10.1016/S0140-6736(96)91558-5.PubMed

108.

Basco LK, Ringwald P: Molecular epidemiology of malaria in Yaounde, Cameroon. VII. Analysis of recrudescence and reinfection in patients with uncomplicated falciparum malaria. Am J Trop Med Hyg. 2000, 63: 215-221.PubMed

109.

Lapierre J: [Polychemoresistant Plasmodium falciparum malaria, successfully treated with a benzonaphthyridine](in French). Nouv Presse Med. 1982, 11: 673-PubMed

110.

Looareesuwan S, Harinasuta T, Chongsuphajaisiddhi T: Drug resistant malaria, with special reference to Thailand. Southeast Asian J Trop Med Public Health. 1992, 23: 621-634.PubMed

111.

Ringwald P, Bickii J, Basco LK: Efficacy of oral pyronaridine for the treatment of acute uncomplicated falciparum malaria in African children. Clin Infect Dis. 1998, 26: 946-953. 10.1086/513942.PubMed

112.

Che LG, Huang KG, Yang HL, Yu L, Lin ZL, Huang R: [Combined use of pyronaridine, sulfadoxine and primaquine in areas with chloroquine-resistant falciparum malaria] (in Chinese). Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 1987, 5: 194-196.PubMed

113.

Han XL, Liu DQ, Feng XP: [Studies on the sensitivity of Plasmodium falciparum to pyronaridine/sulfadoxine/pyrimethamine in vitro] (in Chinese). Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2000, 18: 8-10.PubMed

114.

Huang ZS, Shao BR, Meng F, Zeng LH, Ye XY, Huang J, Shi XH, Guo RN, Li X, Xing QF: [Effects of combined dose of pyronaridine/sulfadoxine/pyrimethamine on falciparum malaria] (in Chinese). Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 1988, 6: 285-288.PubMed

115.

Pang XJ, Liu QJ, Chen QY, Cai XZ, Lin KH, Ou FZ, Liu YP, Fu SG, Liu XM, Liu HH: Efficacy of combined use of pyronaridine, sulfadoxine and pyrimethamine in the treatment of falciparum malaria on Hainan Island. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 1988, 6: 289-291.PubMed

116.

Yang H, Yang P, Yang Y: In vitro sensitivity of Plasmodium falciparum to mefloquine, quinine, amodiaquine, chloroquine, pyronaridine and sulfadoxine/pyrimethamine in south Yunnan. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 1994, 12: 140-142.PubMed

117.

Chen L, Dai ZR, Qian YL, Ma ZM, Guo FC, Liao ZH, Fu DD, Ma DQ, Pang XJ: [Observation on the efficacy of combined use of some new antimalarials for the treatment of falciparum malaria in Hainan Province] (in Chinese). Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 1989, 7: 81-84.PubMed

118.

Liu DQ, Lin SG, Feng XP, Chen WJ, Chen PL, Wu HM, Chen C, Liu J: [Study on treatment of multi-drug resistant falciparum malaria by using a combination of dihydroartemisinin and pyronaridine] (in Chinese). Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2002, 20: 193-196.PubMed

119.

Krudsood S, Looareesuwan S, Gaye O, Tjitra E, Bojang K, Socheat D, Piola P: Results of a randomised, multicentre, phase II, doseranging clinical study to assess the safety and efficacy of fixed dose, orally administered pyronaridine and artesunate in adult patients with acute uncomplicated Plasmodium falciparum malaria [Abstract 1004]. American Society of Tropical Medicine and Hygiene 56th Annual Meeting; 4–8 November; Philadelphia, PA, USA. 2007

120.

Duparc S, Borghini-Fuhrer I, Craft JC, Arbe-Barnes SJ, Miller RM, Schin C, Fleckenstein L: Efficacy of pyronaridine-artesunate in clincial trials in patients with uncomplicated acute Plasmodium falciparum or Plasmodium vivax malaria: results of an intergrated analysis [Abstract 300]. 2009, Washington DC, USA: In Americian society of Tropical Medicine and Hygiene 58th Annual meeting 18-22 November

121.

Tshefu AK, Gaye O, Kayentao K, Thompson R, Bhatt KM, Sesay SS, Bustos DG, Tjitra E, Bedu-Addo G, Borghini-Fuhrer I, Duparc S, Shin CS, Fleckenstein L, Pyronaridine-artesunate Study Team: Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet. 2010, 375: 1457-1467. 10.1016/S0140-6736(10)60322-4.PubMed

122.

Rueangweerayut R, Phyo AP, Uthaisin C, Poravuth Y, Binh TQ, Tinto H, Penali LK, Valecha N, Tien NT, Abdulla S, Borghini-Fuhrer I, Duparc S, Shin CS, Fleckenstein L, Pyronaridine–Artesunate Study Team: Pyronaridine-artesunate versus mefloquine plus artesunate for malaria. N Engl J Med. 2012, 366: 1298-1309. 10.1056/NEJMoa1007125.PubMed

123.

Huei BL, Shen SL, Wang KS, Gao SF, Cao SZ: The radical efficacy of pyronaridine-primaquine combination in tertian malaria. Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 1984, 2: 260-262.PubMed

124.

Liu Y, Wan C, He J, Hu Y, Jia J, Jiang W, Lo M, Shi W: The efficacy of three therapeutic regimens in treating vivax malaria patients. Chinese Journal of Parasitic Disease Control. 1990, 3: 267-270.

125.

Poravuth Y, Socheat D, Rueangweerayut R, Uthaisin C, Pyae Phyo A, Valecha N, Rao BH, Tjitra E, Purnama A, Borghini-Fuhrer I, Duparc S, Shin CS, Fleckenstein L: Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial. PLoS One. 2011, 6: e14501-10.1371/journal.pone.0014501.PubMedCentralPubMed

126.

Larrey D, Castot A, Pessayre D, Merigot P, Machayekhy JP, Feldmann G, Lenoir A, Rueff B, Benhamou JP: Amodiaquine-induced hepatitis. A report of seven cases. Ann Intern Med. 1986, 104: 801-803.PubMed

127.

Arbe-Barnes SJ: Results of Central ECG review of two phase II Pyramax studies. XVIIth International congress for Tropical Medicine and Malaria v. 2008, 58: Abstract # P434 Jeju Island Korea

128.

Ribeiro IR, Olliaro P: Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials. Med Trop. 1998, 58: 50-53.

Title: Review of pyronaridine anti-malarial properties and product characteristics
Publication date: 01-12-2012
Published in: Malaria Journal / Issue 1/2012
Electronic ISSN: 1475-2875
DOI: https://doi.org/10.1186/1475-2875-11-270

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Review of pyronaridine anti-malarial properties and product characteristics

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

Selection of mosquito life-histories: a hidden weapon against malaria?

Copeptin does not accurately predict disease severity in imported malaria

The fitness of African malaria vectors in the presence and limitation of host behaviour

Automated red blood cell exchange as an adjunctive treatment for severe Plasmodium falciparum malaria at the Vienna General Hospital in Austria: a retrospective cohort study

Biological activities of nitidine, a potential anti-malarial lead compound

Malaria prevalence among pregnant women in two districts with differing endemicity in Chhattisgarh, India

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page